Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study

Eye and Vision
Panagiota NtontiGeorgios Labiris

Abstract

Recent artificial tear preparations have provided 0.2% concentration of sodium hyaluronate. However, no published data exist on their potential superiority against 0.1% in alleviating dry-eye-disease symptoms in cataract extraction surgery. A total of 180 patients that underwent cataract extraction surgery were randomly divided into 2 groups according to their postoperative regime: Study group (SG) received fixed combination of tobramycin and dexamethasone (FCTD) quid for 3 weeks, and additionally 0.2% sodium hyaluronate provided in the COMOD® device quid for 6 weeks. Control group (CG) received fixed combination of tobramycin and dexamethasone (FCTD) quid for 3 weeks, and additionally 0.1% sodium hyaluronate provided in the COMOD® device quid for 6 weeks. The following indexes were evaluated at 3 postoperative checkpoints: 1) Surface discomfort index (SDI) which was derived by four direct 10-scale Likert-type questions that were addressed to the patient and pertained to: a) foreign body sensation (FBS), b) blinking discomfort (BD), c) stinging sensation (SS), d) tearing sensation (TS), 2) Tear break-up time (TBUT), 3) Schirmer's test, 4) Central corneal thickness (CCT), and 4) Central Corneal Sensitivity (CCS). Both groups sho...Continue Reading

References

Jun 29, 2005·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Michael E JohnsonMike Boulton
Sep 13, 2006·Archives of Ophthalmology·Adrienne WilliamsPaul P Lee
Feb 6, 2007·Journal of Cataract and Refractive Surgery·Yizhi LiuYangfa Zeng
Oct 13, 2007·European Journal of Ophthalmology·F I CamesascaUNKNOWN Italian Betamethasone-Chloramphenicol vs Dexamethasone-Tobramycin Combination Study Group
Jul 25, 2008·Cornea·David R Hardten
Dec 2, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·W Andrew MaxwellPatricia A Meuse
Jun 6, 2009·Eye·D GuptaT Eke
Mar 17, 2010·Contact Lens & Anterior Eye : the Journal of the British Contact Lens Association·M GuillonS Ho
Jul 15, 2011·Current Medical Research and Opinion·Steven M SilversteinUNKNOWN Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group
Dec 3, 2011·The British Journal of Ophthalmology·Donatella Pascolini, Silvio Paolo Mariotti
Jun 21, 2013·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Wei-Ting HoI-Jong Wang
Aug 31, 2013·Journal of Cataract and Refractive Surgery·Anders BehndigMarie-José Tassignon
Nov 20, 2013·Ophthalmology·Gary C BrownPhilip A Lieske
Nov 23, 2013·PloS One·Ngamjit KasetsuwanSupharat Jariyakosol
Oct 22, 2014·Current Opinion in Ophthalmology·Christopher T Hood, Alan Sugar
Feb 26, 2015·Anais Da Academia Brasileira De Ciências·Juliana L DreyfussJoão R Martins
Nov 17, 2015·Current Opinion in Ophthalmology·Christine SutuNatalie A Afshari
Dec 9, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yuli ParkHyun Seung Kim
Feb 3, 2018·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Eric CarlsonAbayomi Ogundele
Jul 24, 2018·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·In Cheon YouKyung Chul Yoon

❮ Previous
Next ❯

Software Mentioned

COMOD
Medcalc

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.